Therapeutic vaccination for glioblastoma elicited by retargeted oncolytic herpes virus.

Up to 45% of malignant primary brain tumors are glioblastomas 1 and its incidence rate is about 4 cases per 100,000 with an increasing trend. 2 3 The 5-year survival rate of glioblastoma patients is still approximately 5.5% in the USA, with a median overall survival of about 1 year, positively correlated to the extent of surgical resection. 4 5 Standard-of-care treatment for glioblastoma includes maximal safe resection followed by radio

also in 63,971 other papers